Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KAdermin is a topical wound-healing medical device available as a powder spray or cream, designed to facilitate the healing of various skin lesions. It features the patented SCX/SILVERSIL CLOREX complex, which combines silicon dioxide functionalized with silver ions and chlorhexidine to provide a broad-spectrum antimicrobial barrier against wound-colonizing pathogens. The formulation also includes kaolin, which acts as an absorbent for wound exudate, and hyaluronic acid, which creates a protective, hydrated film that supports spontaneous tissue regeneration and re-epithelialization. KAdermin is indicated for the treatment of surgical wounds, ulcers, minor burns, abrasions, and other exuding skin lesions. Clinical research has specifically demonstrated its utility in managing pain and promoting healing at split-thickness skin graft donor sites.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KAdermin.